SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Axel Dignass  1     Silvio Danese  2     Katsuyoshi Matsuoka  3     Marc Ferrante  4     Millie Long  5     Isabel Redondo  6     Theresa Hunter Gibble  6     Richard Moses  6     Xingyuan Li  6     Nathan Morris  6     Catherine Milch  6     Maria T. Abreu  7    
1 Agaplesion Markus Krankenhaus, Frankfurt/ Main, Germany
2 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
3 Tokyo Medical and Dental University, Tokyo, Japan
4 University Hospitals Leuven, Leuven, Belgium
5 University of North Carolina at Chapel Hill, Chapel Hill, United States
6 Eli Lilly and Company, Indianapolis, United States
7 University of Miami, Miller School of Medicine, Miami, United States

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing